Zheng Y, Luo S, Xu M, He Q, Xie J, Wu J
Acta Pharm Sin B. 2024; 14(9):3876-3900.
PMID: 39309496
PMC: 11413706.
DOI: 10.1016/j.apsb.2024.06.015.
Sallard E, Aydin M
Front Cell Infect Microbiol. 2024; 14:1388222.
PMID: 38988815
PMC: 11234472.
DOI: 10.3389/fcimb.2024.1388222.
Zhang F, Shi T, Zhang Z, Wang S, Liu J, Li Y
Appl Microbiol Biotechnol. 2024; 108(1):231.
PMID: 38396242
PMC: 10891252.
DOI: 10.1007/s00253-024-13070-0.
Gambirasi M, Safa A, Vruzhaj I, Giacomin A, Sartor F, Toffoli G
Vaccines (Basel). 2024; 12(1).
PMID: 38250839
PMC: 10821404.
DOI: 10.3390/vaccines12010026.
Miguelena Chamorro B, Hameed S, Dechelette M, Claude J, Piney L, Chapat L
Immunohorizons. 2023; 7(11):788-805.
PMID: 38015460
PMC: 10696420.
DOI: 10.4049/immunohorizons.2300091.
Cracking the intestinal lymphatic system window utilizing oral delivery vehicles for precise therapy.
Miao Y, Xu T, Gong Y, Chen A, Zou L, Jiang T
J Nanobiotechnology. 2023; 21(1):263.
PMID: 37559085
PMC: 10413705.
DOI: 10.1186/s12951-023-01991-3.
Recent progress in application of nanovaccines for enhancing mucosal immune responses.
Du G, Qin M, Sun X
Acta Pharm Sin B. 2023; 13(6):2334-2345.
PMID: 37425056
PMC: 10326163.
DOI: 10.1016/j.apsb.2022.08.010.
Gut distress and intervention communications of SARS-CoV-2 with mucosal exposome.
Moon Y
Front Public Health. 2023; 11:1098774.
PMID: 37139365
PMC: 10150023.
DOI: 10.3389/fpubh.2023.1098774.
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Horvath D, Temperton N, Mayora-Neto M, da Costa K, Cantoni D, Horlacher R
Sci Rep. 2023; 13(1):4648.
PMID: 36944687
PMC: 10029786.
DOI: 10.1038/s41598-023-31198-3.
Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines.
Ou B, Yang Y, Lv H, Lin X, Zhang M
BioDrugs. 2023; 37(2):143-180.
PMID: 36607488
PMC: 9821375.
DOI: 10.1007/s40259-022-00575-1.
Mucosal delivery of nanovaccine strategy against COVID-19 and its variants.
Lee J, Khang D
Acta Pharm Sin B. 2022; .
PMID: 36438851
PMC: 9676163.
DOI: 10.1016/j.apsb.2022.11.022.
Development and Evaluation of a Novel Diammonium Glycyrrhizinate Phytosome for Nasal Vaccination.
Chen X, Fan X, Li F
Pharmaceutics. 2022; 14(10).
PMID: 36297436
PMC: 9612344.
DOI: 10.3390/pharmaceutics14102000.
Nanovesicles-Mediated Drug Delivery for Oral Bioavailability Enhancement.
Ren Y, Nie L, Zhu S, Zhang X
Int J Nanomedicine. 2022; 17:4861-4877.
PMID: 36262189
PMC: 9574265.
DOI: 10.2147/IJN.S382192.
Surface Modification of Biodegradable Microparticles with the Novel Host-Derived Immunostimulant CPDI-02 Significantly Increases Short-Term and Long-Term Mucosal and Systemic Antibodies against Encapsulated Protein Antigen in Young Naïve Mice after....
Parriott J, Stewart J, Smith D, Curran S, Bauer C, Wyatt T
Pharmaceutics. 2022; 14(9.
PMID: 36145590
PMC: 9502690.
DOI: 10.3390/pharmaceutics14091843.
The Biocomplex Assembled from Antigen Peptide and Toll-like Receptor Agonist Improved the Immunity against Pancreatic Adenocarcinoma .
Feng W, Yu H, Xue T, Wu C, Ren F, Cui G
J Oncol. 2022; 2022:2965496.
PMID: 36059807
PMC: 9436581.
DOI: 10.1155/2022/2965496.
Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.
Huang M, Zhang M, Zhu H, Du X, Wang J
Acta Pharm Sin B. 2022; 12(9):3456-3474.
PMID: 35818435
PMC: 9259023.
DOI: 10.1016/j.apsb.2022.07.002.
Bioavailability by design - Vitamin D liposomal delivery vehicles.
Dalek P, Drabik D, Wolczanska H, Forys A, Jagas M, Jedruchniewicz N
Nanomedicine. 2022; 43:102552.
PMID: 35346834
PMC: 8957331.
DOI: 10.1016/j.nano.2022.102552.
Targeting the Gut Mucosal Immune System Using Nanomaterials.
McCright J, Ramirez A, Amosu M, Sinha A, Bogseth A, Maisel K
Pharmaceutics. 2021; 13(11).
PMID: 34834170
PMC: 8619927.
DOI: 10.3390/pharmaceutics13111755.
An update on oral drug delivery intestinal lymphatic transport.
Zhang Z, Lu Y, Qi J, Wu W
Acta Pharm Sin B. 2021; 11(8):2449-2468.
PMID: 34522594
PMC: 8424224.
DOI: 10.1016/j.apsb.2020.12.022.
as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines.
Villena J, Li C, Vizoso-Pinto M, Sacur J, Ren L, Kitazawa H
Microorganisms. 2021; 9(4).
PMID: 33810287
PMC: 8067309.
DOI: 10.3390/microorganisms9040683.